ESH Video

#ESHMM2022 STARTS IN 2 WEEKS! REGISTER NOW!

September 22, 2022
 

6th Translational Research Conference

MULTIPLE MYELOMA

 

October 7-9, 2022
Mandelieu-La Napoule, France

#ESHMM2022


Chairs: Maria-Victoria Mateos (Salamanca), Philippe Moreau (Nantes),
Vincent Rajkumar (Rochester)
 

REGISTER NOW!
The Conference starts in 2 weeks!
Don’t miss the opportunity, you still have time to register!

Join our international faculty of renowned Experts in South of France
to get the latest update on Multiple Myeloma!
The programme starts on Friday, October 7th at 08:45 am CEST!


 

Meet our faculty!




About the Conference:

An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of Multiple Myeloma and plasma disorders, from pathophysiology to diagnosis and therapy, including current challenges and new perspectives.

The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for in-depth scientific discussion and interaction. Registered participants will further benefit from a variety of opportunities for informal scientific interaction with the world’s leading experts in the field, including during small Meet the Expert sessions and Mentored Posters Walks.



Conference main topics:
• Smoldering Myeloma
• Diagnosis of Multiple Myeloma
• Frontline therapy in patients not eligible for autologous stem cell transplantation
• Frontline therapy in patients eligible for autologous stem cell transplantation
• MRD and the Microenvironment
• Relapsed Multiple Myeloma
• The Future: Recent Clinical Trials in Relapse
• Data Management Issues
• Plasma Cell Disorder

Learning objectives:
• Update on the pathophysiology of myeloma and how the disease is evolving from MGUS and SMM
• Update on the diagnostic criteria and the use of new assessments in the diagnostic process
• Treatment of young myeloma patients
• Treatment of elderly and frail myeloma patients
• Optimal sequencing at the relapse
• To know what is the role of new immunotherapic approaches and how will they fit in the landscape
• Role of novel drugs under development
• Latest updates in other plasma cell disorders beyond myeloma


For more information, click here!

 
 
With the support of*:



Premium Conference Partner
*******



Diamond Conference Partner
*******

Emerald Conference Partner
*******



Ruby Conference Partner
*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.